Let's take a look at the Emerging Transformative Therapies around Key Cancers

The number of emerging transformative therapy clinical trials are on the rise for the past few years. The therapies target multiple tumors and it’s difficult to get a clear picture of the leading tumors within these therapies.

Let’s have a closer look at the following list of therapies based on the number of clinical trials:

• 1. Gene Therapy

• 2. Immunotherapy

• Cell Therapy

• Cell Therapy (CART)

• Checkpoint Inhibitors

• Immunomodulatory drugs (IMiDs)

• LADD

• T-Cell Engaging Bi-specifics

Top 5 leading tumors: · Lymphoma (14.52%), Leukemia (12.03%), Lung Cancer (11.19%), Multiple Myeloma (11.02%), Melanoma (8.14%)

---

Breakdown by Gene Therapy

Top 5 leading Tumors: Ovarian Cancer (17.65%), Melanoma (11.77%), Pancreatic Cancer (7.85%), Brain Tumors (9.8%), Lung Cancer, Head and Neck Cancer, Endometrial Cancer, Breast Cancer (5.8%)

---

Breakdown by Checkpoint Inhibitors

Top 5 leading tumors: Melanoma (12.0%), Lung Cancer (17.4%), Lymphoma (8.7%), Leukemia (6.5%), Head and Neck Cancer (6.52%)

---

Breakdown by Cell Therapy

Top 5 leading tumors: Leukemia (14.32%), Lymphoma (11.2%), Lung Cancer (9.96%), Melanoma (9.34%), HCC (7.47%)

---

Breakdown by Cell Therapy Drugs in Lung Cancer:

What drugs do we foresee in Lung Cancer in the future?

Leading Drugs: DC-CIK, GSK3377794, Tarvacin, PD-1 knockout engineered T cells